Ovid Therapeutics Inc. · NASDAQ:OVID

Ovid Therapeutics — Investor Presentation (March 2021)

9 slides from Ovid Therapeutics's investor presentation, Mar 3, 2021

  1. Slide 1: Ovid Therapeutics Corporate Overview

    Ovid Therapeutics Corporate Overview March 3, 2021 ©2021 OVID THERAPEUTICS INC. | ALL RIGHTS RESERVED 1 March 2021 Exhibit 99.1

  2. Slide 2: Disclaimers and Forward-Looking Statements

    Disclaimers and Forward-Looking Statements ©2021 OVID THERAPEUTICS INC. | ALL RIGHTS RESERVED This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “may,” “will,” “believe,” “expect,” “plan,” “anticipate” and s

  3. Slide 3: Transformative $856M+ Transaction with Takeda

    Transformative $856M+ Transaction with Takeda ©2021 OVID THERAPEUTICS INC. | ALL RIGHTS RESERVED 3 March 3, 2021 Captures significant value Eliminates future obligations Delivers strong balance sheet Accelerates development of state-of-the-art next generation pipeline Anticipates multiple INDs begin

  4. Slide 4: Evolves Our Relationship with Takeda

    1. Agreement subject to closing conditions and regulatory approvals Evolves Our Relationship with Takeda 4 Global Collaboration R&D: 50/50 cost sharing + milestones to Takeda Commercialization: Profit Share Executed multiple clinical trials enabling pivotal studies Ovid to receive up to $856M in pay

  5. Slide 5: Transaction Is a Steppingstone to Advance Our Mission

    Transaction Is a Steppingstone to Advance Our Mission ©2021 OVID THERAPEUTICS INC. | ALL RIGHTS RESERVED 5 FUNDS OVID’S NEXT GENERATION NEUROSCIENCE PIPELINE AND SOURCING OF EXTERNAL INNOVATION Supports filing of three neuroscience INDs in three years Enables sourcing of external innovation to grow

  6. Slide 6: Continue Building Our Next Generation Clinical Pipeline

    Continue Building Our Next Generation Clinical Pipeline ©2021 OVID THERAPEUTICS INC. | ALL RIGHTS RESERVED March 3, 2021 Focus on neuroscience indications with high unmet need Target first-in-class/best-in-class therapeutics Leverage academic collaborations to accelerate research and development Ovi

  7. Slide 7: Experienced Management Team

    Experienced Management Team ©2021 OVID THERAPEUTICS INC. | ALL RIGHTS RESERVED 7 Jeremy Levin DPhil, MB Bchir Chairman, CEO Amit Rakhit MD, MBA President, CMO Jason Tardio MBA Chief Commercial Officer Jeffrey Rona Chief Business Officer Thomas Perone JD GC, Corporate Secretary, and CCO Holly Roberts

  8. Slide 8: Strategy Supported by Strong Balance Sheet and Experienced Team

    Strategy Supported by Strong Balance Sheet and Experienced Team ©2021 OVID THERAPEUTICS INC. | ALL RIGHTS RESERVED 8 Transformative agreement for soticlestat with Takeda Ovid eligible to receive up to $856M: Includes $196M upfront and additional payments upon achieving regulatory / commercial milest

  9. Slide 9: Ovid Therapeutics Corporate Overview

    Ovid Therapeutics Corporate Overview MARCH 2021 ©2021 OVID THERAPEUTICS INC. | ALL RIGHTS RESERVED 9 March 2021

Ovid Therapeutics — Investor Presentation (March 2021) on 6ix